Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 291–300 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 291
- Medicine slug
- cevimeline
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 1
- Recorded readings
6L/kg
- Numeric value
- 6
- Unit
- L/kg
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:990887c1-11ce-4a73-83b4-0ffc5a900c85 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7432a48-1142-431e-997f-8419dc724824 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fa69ad5-7fa7-4078-9328-aacbb0d145a4 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51307f82-66f2-41c7-80ff-174d7e50f7ee (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61dd5ee1-cf89-43ea-ada4-4e4a4d9d133b (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d08d8aa5-76a4-417a-a308-7d195865522f (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6 L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efc2bb24-4dda-4781-bef5-fcd9abf082dd (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcaaec18-4ee1-4cfd-84da-8fe3b8c54fc4 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f15cb50-5917-c928-e063-6294a90ab284 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is < 20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dac32a9b-05b8-42c2-9a29-d885a9279456 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe30c870-a060-4a5b-ae61-6a9933854419 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6 L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b429ea7-1c7c-47a4-803c-2546736f5c36 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75ae16d6-8822-4581-b747-ae894a45cdea (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71ada1b0-3344-4202-9277-57f1a37402c1 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6 L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fbcf1a7-5b8b-42fb-b764-4b529e7d1a99 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca0409bc-2685-4ffd-b806-04898902a597 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6 L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4bd942a-1339-40c5-8fd4-850da5a69635 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:773a19e8-4c3e-4414-99a6-aea98c9790ee (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6L/kg and is <20% bound to human plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1167360c-7e0f-4619-9d1a-ad4ee56cab71 (opens source in a new tab)
Cevimeline label
Version not recorded · Effective date not recorded
Distribution: Cevimeline has a volume of distribution of approximately 6 L/kg and is <20% bound to human plasma proteins.
Projected row 292
- Medicine slug
- chlordiazepoxide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 1
- Recorded readings
48 hours
- Numeric value
- 48
- Unit
- hours
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a57a5046-f73b-10a9-e053-2a95a90ad72f (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d4cab96-8a67-4d26-a9cc-b1a02fb6c146 (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9aba3135-00ff-47ba-b926-55eb16b361bf (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53c278b6-d22d-79bd-e063-6294a90a82cd (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8255992f-3256-4558-bd0d-cfe350d95f25 (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43daab7a-3809-4b13-b015-4806912c3c4a (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1eb5eb7a-8c5f-43a3-9b9f-6321cdb6f6c7 (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e64d2d8-b12c-5639-e053-2a95a90aab80 (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3ff8641-ae8a-4016-acb1-cb1b7890f5ed (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54d76424-7fab-c000-e063-6294a90af43e (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74c4320d-c90d-436b-97da-07496ba88aed (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68c7d8a7-08b3-4a1a-acbd-09bbe67b8d4a (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e198c16-a929-4028-8f96-25dd23f74b10 (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cba55889-e81e-404d-974b-4af484eccfb1 (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f04714bc-4ce0-4693-9cd8-578919325474 (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cbd7cee-c4d7-4c95-93d8-09428169b937 (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd5f82b0-5a56-4728-941a-c8c2a0d51cc4 (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:511264f5-024b-350a-e063-6394a90a51e9 (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60abf20f-0c6c-43b9-8b55-f4957e2a655d (opens source in a new tab)
Chlordiazepoxide label
Version not recorded · Effective date not recorded
It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours.
Projected row 293
- Medicine slug
- chlorthalidone
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 78
- Source count
- 78
- Agreement rate
- 0.974359
- Recorded readings
40 hours
- Numeric value
- 40
- Unit
- hours
- Source records
- 76
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 76 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2de92cea-8f03-4af0-9d91-d4578510cc53 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08b7ee65-53a5-ffbb-e063-6294a90ad4ee (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa16c3fe-c00b-4b49-bfe3-3b3f93bd647a (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98f4a14c-2863-4068-bd35-aaedcc872680 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b1ff6c9-2367-4446-87a6-be86c0efd8e1 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14f9e2c6-ceb0-4306-9936-ca109912de12 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50936b5f-3eb8-4ff8-96b3-0aa4a8f77a98 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c1bfe5-b5c8-43c0-9428-62337095b2bd (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 mg to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:583992c2-b789-4267-9a8f-c1ee5db3f29f (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f319c0c7-182b-70ee-e053-2a95a90ac5ef (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68244f44-42e9-46b6-86f8-85ab0c4b2b26 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5796482-ad1f-437a-ae80-c288880f4100 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c76c7a6-abfb-4dc1-ad5a-d7d00cb832cb (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ccba8ab-4c34-af52-e063-6394a90a78d3 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd92c59b-3a65-47c3-b3c8-37090b4ae464 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d09c992-22f7-41e1-a836-380712f242c0 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d07eea8b-361b-486a-a572-3bf4a257f431 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db169e46-9f6e-490e-856f-f60ec9a31980 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36ef8d83-45f2-4873-b7cb-1be096d14d18 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0baac2aa-06c4-489e-a3f9-fe9d20cf61a2 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f46fd743-3661-41b7-b12d-30d96692f0ee (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd2e4486-0720-4d09-b4f5-472c4478af0e (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e727d42f-e4e1-4cf6-9d7a-6ec2333bc6d1 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ba595d4-b105-4d52-90dd-0fb8bda1fe1b (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ccc5376-5fb0-dd09-e063-6294a90af563 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 mg to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d867a784-54f0-4cce-9306-f92de095e855 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:193c85ba-43c2-4be2-82cf-7b394a83390e (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e9e9ced-6960-4d2f-bb23-ef8b2435da75 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5de362df-8fb9-4421-864c-7ea06339d6e7 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dea660bd-d4cc-4c5b-9c6d-674a6dc1c9c2 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef8023a3-b2be-436e-9085-576781950665 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcd2b6f8-533a-4f50-b3e6-80427e6c19ac (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:401ae38b-2eb8-c9fc-e063-6294a90af220 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:284f4707-14ab-426f-80d6-79f1186419f9 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 mg to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a73613a3-914f-481a-8e40-8d782bcea03a (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf09d68f-af7a-4057-92f1-13f1ef85d532 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da0fe4da-a4f3-4aa8-84f4-4d31c5cbdb0e (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71b1d074-0521-4cd1-beb5-fedd61f52eca (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f96b2d0b-a141-4efb-8ccc-c447dfc6024a (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:972b801e-c4f2-4bd6-e053-2a95a90a53bb (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:645734ab-d6aa-4368-9a5a-b550e2717770 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5441e163-459a-46b0-87a9-e9879091bf3c (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01337f79-4b3d-4749-a82b-8d56c1aec179 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca0df4ae-c424-44d2-8611-1637f1a101a8 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:165e5993-eb9d-4664-97dc-574ae5e0e946 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1ff748d-36e9-4327-aa8a-e8fb22a9d637 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f309b5df-ce39-0d55-e053-2995a90a7878 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da829c8c-ae13-510b-e053-2995a90a70b8 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0e316f6-96d1-4a89-a3b9-f4f0b4c9c833 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a304de67-cd2b-4933-937e-4eeecf6cda40 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3ff03fd-bbab-4c8d-b24d-40c611db3bb3 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56635d7a-1fff-4d1f-bf2c-def4b1ad8208 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8e2b475-a8e9-4aa9-b4e9-66d746bbdc70 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d61367af-530b-4e5e-8e71-11c93f75ecf1 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:648f005f-1eae-4718-bc3a-2587d706fae2 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e5cc0d8-6575-4675-bd8b-9a21b206aae1 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f19b9a1c-1a43-4317-a016-6104391730dc (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac431d1b-b307-46fe-a3a9-29f40fe6742b (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b98d1a1-9d3d-41d2-a5e9-744b851d30d4 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1043a72-8e64-49da-a7e4-eadee083022e (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1ab541b-7515-4888-b3e0-aca52875562d (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01065eda-7515-46bc-b858-a062c3aa35bd (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df6271ff-f111-fd4a-e053-2a95a90a4b51 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15dd224a-87ad-48dc-80b1-e8382a452c4c (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d8e26e6-7314-4799-b137-934926d343b0 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb7112ae-3a37-4525-8c7f-c0f4100ffc0a (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3f053cd-7118-4602-9b15-7f7fd143b8c2 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 mg to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ea42479-84f4-434d-b65b-de34a7a57926 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03204a70-d53b-0e44-e063-6394a90a2aab (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 mg to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:deab1d3e-759f-480e-e053-2995a90a0a75 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d104583e-e983-4230-b6d1-4455ee1060a5 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5979af5a-0c5b-40f9-bb67-2d462e1cefb7 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8373bde-c8c9-445a-8933-49394023414a (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3b09f77-8ad2-233d-e053-2995a90a60c8 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 mg to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da50019b-60ea-47b3-a355-4ab48efcbe3d (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 to 200 mg dose is 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:180cc3c7-6ab7-481b-b860-b20d3599e53f (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
The mean half-life following a 50 mg to 200 mg dose is 40 hours.
40 to 60 hours
- Numeric value
- 40
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc5a0299-115b-4e60-bb3f-c75a95c51c15 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
Elimination The mean plasma half-life of chlorthalidone is about 40 to 60 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f0f3ee0-f5a6-4bda-8160-a77744e9fa46 (opens source in a new tab)
Chlorthalidone label
Version not recorded · Effective date not recorded
Elimination The mean plasma half-life of chlorthalidone is about 40 to 60 hours.
Projected row 294
- Medicine slug
- ciclesonide
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
1%
- Numeric value
- 1
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f6112fb-78ef-43cf-8ae3-36370eb45468 (opens source in a new tab)
Ciclesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption : Ciclesonide and des-ciclesonide have negligible oral bioavailability (both are less than 1%) due to low gastrointestinal absorption and high first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15fefd46-ac7e-40d0-b635-e6c3d653c666 (opens source in a new tab)
Ciclesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption : Ciclesonide and des-ciclesonide have negligible oral bioavailability (both less than 1%) due to low gastrointestinal absorption and high first-pass metabolism.
Projected row 295
- Medicine slug
- ciclopirox
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 24
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
5.5 hours
- Numeric value
- 5.5
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:933785c2-22ee-4e3a-a46a-e7cd545b08ac (opens source in a new tab)
Ciclopirox label
Version not recorded · Effective date not recorded
Approximately 3% of the applied ciclopirox was excreted in the urine within 48 hours after application, with a renal elimination half-life of about 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51993bbb-f145-4662-8138-4db774cc0513 (opens source in a new tab)
Ciclopirox label
Version not recorded · Effective date not recorded
Approximately 3% of the applied ciclopirox was excreted in the urine within 48 hours after application, with a renal elimination half-life of about 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c22416e-4293-4ba5-a983-137cbc6022db (opens source in a new tab)
Ciclopirox label
Version not recorded · Effective date not recorded
Approximately 3% of the applied ciclopirox was excreted in the urine within 48 hours after application, with a renal elimination half-life of about 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6a02568-867b-4c7b-890f-5d28bf0b363d (opens source in a new tab)
Ciclopirox label
Version not recorded · Effective date not recorded
Approximately 3% of the applied ciclopirox was excreted in the urine within 48 hours after application, with a renal elimination half-life of about 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:810bfb01-a69d-4b00-ac2d-b92e7ddad9f9 (opens source in a new tab)
Ciclopirox label
Version not recorded · Effective date not recorded
Approximately 3% of the applied ciclopirox was excreted in the urine within 48 hours after application, with a renal elimination half-life of about 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:808733e7-9402-4f9b-99ce-ca6d04ad4aee (opens source in a new tab)
Ciclopirox label
Version not recorded · Effective date not recorded
Approximately 3% of the applied ciclopirox was excreted in the urine within 48 hours after application, with a renal elimination half-life of about 5.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9861c88d-528f-4e30-8c1e-56ac3afec76c (opens source in a new tab)
Ciclopirox label
Version not recorded · Effective date not recorded
Approximately 3% of the applied ciclopirox was excreted in the urine within 48 hours after application, with a renal elimination half-life of about 5.5 hours.
Projected row 296
- Medicine slug
- cilostazol
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
95 to 98%
- Numeric value
- 95
- Unit
- %
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77e77eaf-5556-43ac-844e-c0e29f02fe07 (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b57d3c1e-e36f-5255-e053-2a95a90ada83 (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc7c2c25-36a1-e3fd-e053-2995a90adabc (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db0278e9-4ece-4aaf-9216-6bcbec58206a (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15ead884-bd4f-7f4b-e063-6394a90a8f81 (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:15478d90-312f-014e-e063-6294a90ae838 (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6292311-9cb2-49ff-b8bf-12e2dbd196cd (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f728395c-684c-4087-a389-c323dbcb72dd (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aec462c8-e225-f520-cae5-80049151c0ff (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53486382-eee0-4cbe-bc4a-a57484e0d5a7 (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ceac1ae3-c343-28ca-c083-b748d21a15e6 (opens source in a new tab)
Cilostazol label
Version not recorded · Effective date not recorded
Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).
Projected row 297
- Medicine slug
- cimetidine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 23
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c2e1f52-4021-4f70-9b2b-63af17094187 (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28fa98b3-6c78-4b7b-9a37-84c879dbf58a (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine tablets is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db482bd8-e68d-3a38-e053-2995a90a38a5 (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine tablets is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8b50bd9-bc1b-4da5-96c5-8eb917c8937f (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d7b6e7d-cf01-70a2-e063-6394a90afbe6 (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:496e258d-a5fd-42da-9a86-73afc8be359b (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28fd7158-a617-436a-8f5c-71ffbaafe527 (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine tablets is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e40bb1f6-338a-42e7-9217-8c32d14ccfd3 (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebd53065-c080-4045-a398-64d3f3b1460f (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine tablets is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ab5ea2b-bd2f-49ec-9e92-033bed998797 (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06c0a509-026f-44e0-9975-a94a8de51d43 (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine tablets is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1d73350-4e7e-428a-90a5-6000fd373a4f (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01997826-7ca1-473e-bfc9-075b14b58a35 (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine tablets is approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf1626a1-ccf6-4759-b2ab-22c7f3873d84 (opens source in a new tab)
Cimetidine label
Version not recorded · Effective date not recorded
The half-life of cimetidine is approximately 2 hours.
Projected row 298
- Medicine slug
- cinacalcet
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
49 hours
- Numeric value
- 49
- Unit
- hours
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f95ae0-84ac-4ae4-b7a0-7590ab919ae1 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b6b3867-9c89-4b6d-b381-dc73e1502821 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:330b4214-dba7-468c-a67e-b1057f4628da (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c288922b-3258-4c1c-bd8a-32a41dd43a63 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86fe67f9-d4e0-4966-a80b-c04bf6bb0ef9 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b920a91f-309f-4f83-a123-525b3bdd55b7 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79b64bbb-3682-4b31-9bb6-03e2c5ac5a2c (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0604423-af02-46dd-b38b-8e0937517304 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d2f2a92-ee1c-084a-e063-6294a90aae96 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0692252e-4cc6-4f16-8a54-aeacd59c3143 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5480ebd3-5b39-4f8b-bb03-05617f6f519f (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45028573-13c4-4c8b-ae62-6c75bba97c81 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ba47b6a-ba49-4d7a-82e1-1c6e49bfa5d7 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff0b9500-085a-4e1e-a2e4-fd918ed70b2e (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44b548ef-1679-4d15-86ad-0d9636b48a45 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93e94a24-fe2f-4ce6-bd1b-0d51be4e74bc (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a561936-494f-4320-bf6e-c36481f1518c (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1cfc943-5b70-4451-a1fc-61e45e669d84 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28262843-b0a8-4ca7-8b92-41b7f0e896b4 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bad4e06-c0a1-4123-83c2-67d3b081e8a9 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c78bfff-7a82-4d1d-bc61-718c3ff3aa92 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e96cfada-3763-4af7-b323-1256926a797c (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:200390f2-7dad-4ecc-a086-c29e18525c01 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0837aabc-e796-0e07-8958-71f1ff6e89bf (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:092553cf-1bcd-4c19-9adf-b46f2bda5c9e (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02b8c11b-99e8-4039-b6fa-a9c38d2f48fa (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60e6264c-723c-49b2-a246-827b15ff219c (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a978cb-d57b-4f1e-ba14-316b6f9abe33 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively.
Projected row 299
- Medicine slug
- cinacalcet
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 0.857143
- Recorded readings
1000 L
- Numeric value
- 1,000
- Unit
- L
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55f95ae0-84ac-4ae4-b7a0-7590ab919ae1 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b6b3867-9c89-4b6d-b381-dc73e1502821 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:330b4214-dba7-468c-a67e-b1057f4628da (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c288922b-3258-4c1c-bd8a-32a41dd43a63 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86fe67f9-d4e0-4966-a80b-c04bf6bb0ef9 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b920a91f-309f-4f83-a123-525b3bdd55b7 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79b64bbb-3682-4b31-9bb6-03e2c5ac5a2c (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0604423-af02-46dd-b38b-8e0937517304 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d2f2a92-ee1c-084a-e063-6294a90aae96 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0692252e-4cc6-4f16-8a54-aeacd59c3143 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45028573-13c4-4c8b-ae62-6c75bba97c81 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ba47b6a-ba49-4d7a-82e1-1c6e49bfa5d7 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44b548ef-1679-4d15-86ad-0d9636b48a45 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93e94a24-fe2f-4ce6-bd1b-0d51be4e74bc (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a561936-494f-4320-bf6e-c36481f1518c (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1cfc943-5b70-4451-a1fc-61e45e669d84 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28262843-b0a8-4ca7-8b92-41b7f0e896b4 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bad4e06-c0a1-4123-83c2-67d3b081e8a9 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c78bfff-7a82-4d1d-bc61-718c3ff3aa92 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e96cfada-3763-4af7-b323-1256926a797c (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:200390f2-7dad-4ecc-a086-c29e18525c01 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02b8c11b-99e8-4039-b6fa-a9c38d2f48fa (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60e6264c-723c-49b2-a246-827b15ff219c (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a978cb-d57b-4f1e-ba14-316b6f9abe33 (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1000 L, indicating extensive distribution.
1,000 L
- Numeric value
- 1,000
- Unit
- L
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5480ebd3-5b39-4f8b-bb03-05617f6f519f (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1,000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff0b9500-085a-4e1e-a2e4-fd918ed70b2e (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1,000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0837aabc-e796-0e07-8958-71f1ff6e89bf (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1,000 L, indicating extensive distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:092553cf-1bcd-4c19-9adf-b46f2bda5c9e (opens source in a new tab)
Cinacalcet label
Version not recorded · Effective date not recorded
The volume of distribution is approximately 1,000 L, indicating extensive distribution.
Projected row 300
- Medicine slug
- ciprofloxacin
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 146
- Source count
- 119
- Agreement rate
- 0.966387
- Recorded readings
70%
- Numeric value
- 70
- Unit
- %
- Source records
- 115
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 115 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e237dd23-faf3-1765-e053-2a95a90ae62d (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
Clinical Pharmacology 12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see MICROBIOLOGY (12.4)]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6971a958-08f0-4712-bf5f-47fe4f76b863 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbcd32c0-bcfd-4cc7-8e81-6612bc0cfc45 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
The absolute bioavailability is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17435f05-f04d-e792-e063-6294a90af145 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c355077-7361-41d0-9e82-eb31beaf5daa (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d17b0e87-b555-4dfb-e053-2a95a90aa5ef (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fd3da0b-7428-ac8f-e053-2a91aa0aed9f (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36d6c27d-45dc-3081-e063-6394a90a87e9 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology (12.4)]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5af16acc-51ce-41ed-b1c4-6b3fb38ef515 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fe3becb-f90e-4187-a8e8-bd0de5a79ad2 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c08b37c3-5f01-47ed-9508-02813bbd008b (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4dd69fb7-802a-4278-a730-c722a3ca3521 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f67d727f-b9ca-aec0-e053-2995a90aab69 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d88a22f4-2f61-17f2-e053-2995a90acd14 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology ( 12.4)]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f600112-168a-4a58-9914-7c01f71894da (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
1 2 . 3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bb1d26e-fad0-4338-8948-3f095d5817a6 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
1 2 . 3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ee1f252-a64e-4b72-a6f7-60298e827222 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:641729a3-6dd3-3a2f-e053-2991aa0a015e (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44e5582d-fff1-0ec9-e054-00144ff88e88 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d358eb18-f4d0-e9ba-e053-2a95a90a435d (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see MICROBIOLOGY (12.4)]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d23e359d-6d12-38f6-e053-2a95a90a0a88 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see MICROBIOLOGY (12.4)]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2efbda2a-fc97-b7c5-e063-6294a90a362d (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
Click here to enter Clinical Pharmacology 12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology (12.4)]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69df48cc-76b6-428e-891a-c25e07d785f8 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acb03e72-ce94-58c5-e053-2a95a90a683a (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d029ad2-a1e8-4c11-a5eb-e2257c6a0ddb (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4972e902-e042-e947-e063-6394a90a1b70 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2d8dcc9-23b0-75bb-e053-2995a90a02c8 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c32ccb5f-b9d7-0aff-e053-2995a90afe6d (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7ac7e18-fd34-44df-8a0e-87dafbc7a2f5 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a05035e1-f941-4f7c-9321-91dd50ab149b (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a70db6c-ae68-49e5-8a4a-b5cd1d4840bd (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2902d14-16bb-46a9-a45a-4f1f9b0ecf4a (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b283d662-9be1-49c7-be03-cb21055314c1 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc768d3e-a7cc-46a2-ae6d-0f5eb2f05406 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb2edaca-6cf2-4100-83f5-8ce142f68e59 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2491e6a9-3415-43b9-b31b-67331f52806a (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dca6149-00ca-480e-a887-6861e40803b9 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d83b127-ef13-4b2c-aa30-0f54937dc240 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2ffa81a-86c5-40b9-8fa0-c889801ef479 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b3b6a9f-259c-4736-b88f-f49d1eb64286 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18414c5a-8153-44f7-b27a-90c290af0a23 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b9b15f7-354b-4049-982b-f6f31751a885 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef468722-68cd-440b-afd7-2285029db41f (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37527eca-115e-4582-88cd-bba851ac6069 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c47250c2-bece-46b5-8b3b-b7c97d9005d8 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa32aafd-e3f5-4be6-9413-c7663c1c2cec (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1057be77-00bb-4839-be3d-c8e11ae531a2 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44b6cefc-7638-4437-95e7-8f239f66a9d4 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c64aa79-d087-4568-904c-3a0638b91e69 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf52e242-199b-4206-e053-2a95a90a1eb7 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a093ca6e-9963-4eea-b60d-6e2f148192ec (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b064286b-fedc-be68-e053-2995a90aae52 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cb05412-372e-4b49-92e1-532caa05f38f (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30caadee-3255-e0e3-e063-6294a90a8061 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c12b316f-811c-48b6-a320-d314991aa74f (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b54c195-71ba-2523-e063-6294a90ada73 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec43739e-7154-45a7-add7-bfb8fb779be8 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfda82e4-8660-447e-a881-b87165a31e9a (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf8d4359-a850-97b7-e053-2a95a90aa66a (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e4402d4-e0d3-9846-3e81-ed46f34137fe (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:348e810c-e572-f3d2-e063-6394a90a0855 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58388197-82f4-0953-e063-6294a90ac52a (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7030109d-5ce0-43f1-a5ed-16a3562acd40 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b5fe0aa-c74f-42f3-a84a-1cb16009aa80 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0136d72-0869-2da0-e053-2995a90af70a (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b996e81b-36ec-4ad7-a7c4-bc6700a06648 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac87e3c7-1e51-4dd1-8b75-dec6536810e3 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f123a2c-3f94-ca2d-e063-6394a90aff68 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fac4466-fbe5-49d2-96e3-e3ac2739bd5b (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:275de35b-5c97-4ff8-a571-42e23c1cd83e (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14c3bc33-201d-492e-9aee-a4d84c813a3d (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae77a5c0-a2ae-770c-e053-2a95a90a6a96 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c611c8c-deed-4904-93f7-f75a2147fbf7 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8eef4f14-e7ef-41be-be57-7993b333e8a9 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e1addcf-6d5b-46c8-812b-558fd847f005 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6bd5021-cf56-4c8a-b5a0-bbc8919740af (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e81341c6-0e25-4860-adda-2d3cebe88d62 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57e5832f-9168-1f24-e063-6294a90aaae6 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:922e9f5c-cc59-4d9e-bf42-a4b900d077ed (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bab9397-b9f3-d309-e053-2991aa0a6612 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4af3894a-8945-4b2d-bdf6-a83bbd415b89 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de0b9579-fb85-e1ce-e053-2a95a90aeecb (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7bc0d20-526c-48ea-b23a-cea9eb7080ff (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ecc693-b8fd-4a7a-8040-e56f801c9353 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:178dc379-e2b8-4b47-9f0c-3fc7fb435c36 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f80ab01d-2533-1b4c-e053-6294a90a6e6a (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6debb60-d885-230b-e053-6394a90ad73a (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47d1e4c5-f669-4aca-9e8c-0d6bb833b859 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a914512b-9a4a-4c53-ab7a-2e2b1ea8a012 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99918613-7936-47dd-8565-9cd6c0cc22e3 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d275175c-691a-4d09-bbb7-50ee819e6727 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e74496f-4dca-4471-be32-c0a14bc62750 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df24efa3-c9a0-4f40-92ce-cc71c708931b (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b3d22dc-df09-4910-8c9b-1204eeedbd68 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7041828f-d4ec-4813-bcac-cb335c6c312a (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e37322b-89d3-4b66-8e1b-c4ad79eed173 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74e2dd24-5c6e-4dde-a2ab-f2d2e61734d8 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d5afeff-3917-43e1-9d12-d70ccab00dcc (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f818ed31-c746-4171-afdf-57a75434e5f1 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26e2d370-f59c-40ae-9c1e-7f8bf1f9fde4 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8b21832-b74f-4f85-a304-b907c9e01e72 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4deea61e-f3ca-b35d-e063-6294a90a9d41 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b281a5c0-5f3e-4e6f-86ac-ed7794aac64c (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:351b41db-622f-a1eb-e063-6294a90a5667 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
Click here to enter Clinical Pharmacology 12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology (12.4)]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d6ec3ee-2205-4d78-bc48-d39f371797c1 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of Ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46dedf2c-26de-0f46-e054-00144ff88e88 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a57066d7-dc2c-d2d0-b003-d9143fcca1c5 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
1 2 . 3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec337816-4f48-4d04-b91d-60f9f5f634da (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5723eaf9-8659-4730-b792-4e4c33690ccb (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fff7a38-2c4e-d343-e063-6294a90aca3c (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42542f65-84a7-fdab-e063-6394a90a1095 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4149d980-a6cd-c06d-e063-6394a90a47a1 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7e5174a-dd01-6050-e053-2a95a90add3f (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see MICROBIOLOGY (12.4)]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a935846-3c97-4517-bc4e-2377f673285e (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.
70 to 80%
- Numeric value
- 70
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f406e796-17d9-4465-b8a7-00d966a4ba74 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of oral ciprofloxacin is within a range of 70 to 80% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7049f870-6741-4a67-8033-398c36126a06 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of oral ciprofloxacin is within a range of 70 to 80% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbbbf939-3219-4515-a48e-ca264daa4d07 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of oral ciprofloxacin is within a range of 70 to 80% with no substantial loss by first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42c758be-4d44-018a-e063-6294a90ae041 (opens source in a new tab)
Ciprofloxacin label
Version not recorded · Effective date not recorded
The absolute bioavailability of oral ciprofloxacin is within a range of 70 to 80% with no substantial loss by first pass metabolism.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=290Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.